Cargando…

A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving Complete Remission with Rituximab-CHOP Chemotherapy

Primary adrenal lymphoma is a very rare extranodal lymphoma; its clinical features consist of a high incidence of bilateral adrenal involvement and diffuse large B-cell lymphoma. We report a patient with primary bilateral adrenal diffuse large B-cell lyphoma who achieved complete remission with R-CH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Kyung Min, Yoon, Dok Hyun, Lee, Seung Geun, Lim, Sung Nam, Sug, Lyu Jin, Huh, Jooryung, Suh, Cheolwon
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2009
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2698205/ https://www.ncbi.nlm.nih.gov/pubmed/19543522 http://dx.doi.org/10.3346/jkms.2009.24.3.525

Ejemplares similares

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma
por: Choi, Eun-Ji, et al.
Publicado: (2017)

Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy
por: Oh, Sukjoong, et al.
Publicado: (2011)

Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study
por: Hwang, Hee Sang, et al.
Publicado: (2021)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems
por: Hwang, Hee Sang, et al.
Publicado: (2014)

Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma
por: Hwang, Hee Sang, et al.
Publicado: (2013)

A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
por: Kim, Jeong Eun, et al.
Publicado: (2012)

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
por: Yoo, Changhoon, et al.
Publicado: (2010)

EBV-positive diffuse large B-cell lymphoma of the elderly with aberrant expression of CD3 and TIA-1
por: Lee, Miji, et al.
Publicado: (2013)

Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
por: Jo, Jungmin, et al.
Publicado: (2014)

Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience
por: Kim, Jeongseok, et al.
Publicado: (2014)

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
por: Seo, Seyoung, et al.
Publicado: (2016)

Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology
por: Ahn, Yongchel, et al.
Publicado: (2017)

CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma
por: Koh, Young Wha, et al.
Publicado: (2014)

Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient
por: Choi, Eunji, et al.
Publicado: (2015)

Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement
por: Ko, Ock Bae, et al.
Publicado: (2008)

Modified Stage Grouping of Diffuse Large B-Cell Lymphoma Involving the Same Side of the Diaphragm in the Rituximab Era
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP
por: Cho, Min-Chul, et al.
Publicado: (2018)

Cluster Containing More Than 20 CD3-Positive Cells in Bone Marrow Biopsy Is a Candidate Prognostic Indicator in Peripheral T-Cell Lymphoma, Not Otherwise Specified
por: Shim, Hyoeun, et al.
Publicado: (2019)

Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)
por: Yoon, Dok Hyun, et al.
Publicado: (2017)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
por: Koh, Young Wha, et al.
Publicado: (2017)

Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy
por: Kim, Tark, et al.
Publicado: (2012)

Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients
por: Jeong, Jae Ho, et al.
Publicado: (2017)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution
por: Kim, Meejeong, et al.
Publicado: (2021)

Primary mediastinal large B-cell lymphoma: a single-center experience in Korea
por: Ahn, Heui June, et al.
Publicado: (2014)

Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kang, Jihoon, et al.
Publicado: (2017)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis
por: Huh, Jin-Young, et al.
Publicado: (2017)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma
por: Lisenko, K., et al.
Publicado: (2017)

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth
por: Lee, Eun Ju, et al.
Publicado: (2014)

Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms
por: Yu, Haifeng, et al.
Publicado: (2021)

Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System
por: Cabrera, María Elena, et al.
Publicado: (2022)

Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma
por: Cho, Hyungwoo, et al.
Publicado: (2016)

Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders–diffuse large B-cell lymphoma
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
por: Li, Xueying, et al.
Publicado: (2019)

JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma
por: Kim, Min-Sun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8d4fmdl6pbb36eebc8g5ng7f3m